Analysis of Tucatinib (Tucatinib) Medical Insurance Reimbursement Price: Patient Burden and Accessibility Outlook

Tucatinib (Tucatinib), an oral small molecule tyrosine kinase inhibitor, is designed to treat HER2 positive breast cancer. It relies on the property of highly selectively inhibiting the HER2 receptor to effectively prevent the growth and spread of cancer cells, bringing new hope to the field of breast cancer treatment. In December 2019, Tucatinib was approved by the U.S. Food and Drug Administration (FDA) and became an important treatment option for patients with advanced or metastatic breast cancer.

However, unfortunately, as of now, tucatinib (tucatinib) has not been officially launched in the Chinese market. This means that domestic patients are temporarily unable to purchase this drug directly through formal channels. But fortunately, patients are still expected to obtain tucatinib (tucatinib) through overseas channels, including original drug and generic drug options.

Talking about price, the price of the original drug tucatinib (tucatinib) is indeed high. Taking the European version as an example, the price of each box is as high as tens of thousands of yuan, which undoubtedly brings a heavy financial burden to many patients. In order to seek more economical treatment options, some patients choose to purchase foreign generic drugs. The price of generic drugs produced in countries such as Laos and Bangladesh is relatively affordable, with each box costing about three to four thousand yuan. These generic drugs are highly similar in ingredients and efficacy to the brand-name drugs, making them a viable option for many patients.

The high price of tucatinib has undoubtedly raised widespread concerns about its accessibility and medical insurance reimbursement. Tucatinib treatment costs approximately $18,500 per month in the United States, and although insurance may partially cover the cost, patients still have to bear significant out-of-pocket costs. In order to reduce the financial burden on patients, Seagen, the manufacturer of tucatinib, and some charities have launched patient assistance programs.

In China, with the advancement of the marketing approval process of tucatinib, once it is approved for marketing, its medical insurance reimbursement issue will undoubtedly become the focus of many patients. The country’s emphasis on and support for innovative anti-cancer drugs is expected to promote the inclusion of tucatinib in the medical insurance catalog. Through the negotiation mechanism, we are expected to see the price of tucatinib be reasonably reduced, thereby further reducing the financial burden on patients. The introduction of tucatinib will be HER2Positive breast cancer patients are offered new treatment options that promise to extend patients' survival and improve their quality of life.